Topoisomerase 2β: A promising molecular target for primary prevention of anthracycline-induced cardiotoxicity

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 1, 2014, Pages 45-52

  Vejpongsa, P ^a   Yeh, E T H ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; IRON; PROTEIN P53; RAZOXANE; REACTIVE OXYGEN METABOLITE; TOPOISOMERASE 2 ALPHA; TOPOISOMERASE 2 BETA; UNCLASSIFIED DRUG;

ANTHRACYCLINE INDUCED CARDIOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; DOUBLE STRANDED DNA BREAK; DRUG EFFECT; DRUG INDUCED DISEASE; ENZYME DEGRADATION; ENZYME INHIBITION; HEART MUSCLE CELL; HUMAN; METASTASIS; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84891009434     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.201     Document Type: Article

References (72)

1. Di Marco, A. et al. 'Daunomycin', a new antibiotic of the rhodomycin group. Nature 201, 706-707 (1964).
2. J acquillat, C., Boiron, M., Weil, M., Tanzer, J., Najean, Y. & Bernard, J. Rubidomycin. A new agent active in the treatment of acute lymphoblastic leukaemia. Lancet 2, 27-28 (1966).
3. Tan, C., Tasaka, H., Yu, K.P., Murphy, M.L. & Karnofsky, D.A. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 20, 333-353 (1967).
4. Von Hoff, D.D., Rozencweig, M., Layard, M., Slavik, M. & Muggia, F.M. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am. J. Med. 62, 200-208 (1977). (Pubitemid 8042834)
5. Yeh, E.T. & Bickford, C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53, 2231-2247 (2009).
6. Cardinale, D. et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109, 2749-2754 (2004). (Pubitemid 38737923)
7. Mackay, B., Ewer, M.S., Carrasco, C.H. & Benjamin, R.S. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct. Pathol. 18, 203-211 (1994). (Pubitemid 24131629)
8. Von Hoff, D.D. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91, 710-717 (1979). (Pubitemid 10218041)
9. Swain, S.M., Whaley, F.S. & Ewer, M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97, 2869-2879 (2003). (Pubitemid 36605157)
10. Doroshow, J.H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43, 460-472 (1983). (Pubitemid 13193830)
11. Keizer, H.G., Pinedo, H.M., Schuurhuis, G.J. & Joenje, H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol. Ther. 47, 219-231 (1990). (Pubitemid 20228581)
12. Wouters, K.A., Kremer, L.C., Miller, T.L., Herman, E.H. & Lipshultz, S.E. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 131, 561-578 (2005). (Pubitemid 43899624)
13. Herman, E.H., Ferrans, V.J., Myers, C.E. & Van Vleet, J.F. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res. 45, 276-281 (1985). (Pubitemid 15196968)
14. Van Vleet, J.F., Ferrans, V.J. & Weirich, W.E. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am. J. Pathol. 99, 13-42 (1980).
15. Dresdale, A.R. et al. Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. Am. J. Clin. Oncol. 5, 657-663 (1982). (Pubitemid 13149997)
16. Herman, E.H., Mhatre, R.M., Lee, I.P. & Waravdekar, V.S. Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart. Proc. Soc. Exp. Biol. Med. 140, 234-239 (1972).
17. Hasinoff, B.B., Hellmann, K., Herman, E.H. & Ferrans, V.J. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem. 5, 1-28 (1998). (Pubitemid 28083490)
18. Herman, E.H., Ferrans, V.J., Young, R.S. & Hamlin, R.L. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res. 48, 6918-6925 (1988). (Pubitemid 19012227)
19. Speyer, J.L. et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl. J. Med. 319, 745-752 (1988).
20. Speyer, J.L. et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. 10, 117-127 (1992).
21. Hensley, M.L. et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 27, 127-145 (2009).
22. Hasinoff, B.B. & Herman, E.H. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc. Toxicol. 7, 140-144 (2007). (Pubitemid 47339861)
23. Link, G., Tirosh, R., Pinson, A. & Hershko, C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J. Lab. Clin. Med. 127, 272-278 (1996). (Pubitemid 126657307)
24. Schroeder, P.E. & Hasinoff, B.B. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925. Cancer Chemother. Pharmacol. 50, 509-513 (2002). (Pubitemid 35435531)
25. Hasinoff, B.B., Patel, D. & Wu, X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic. Biol. Med. 35, 1469-1479 (2003). (Pubitemid 37452472)
26. Minotti, G., Ronchi, R., Salvatorelli, E., Menna, P. & Cairo, G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res. 61, 8422-8428 (2001). (Pubitemid 33131119)
27. Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D. & Liu, L.F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226, 466-468 (1984). (Pubitemid 14012819)
28. Liu, L.F. & Wang, J.C. Supercoiling of the DNA template during transcription. Proc. Natl. Acad. Sci. U.S.A. 84, 7024-7027 (1987).
29. Drake, F.H. et al. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J. Biol. Chem. 262, 16739-16747 (1987). (Pubitemid 18006076)
30. Capranico, G., Tinelli, S., Austin, C.A., Fisher, M.L. & Zunino, F. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim. Biophys. Acta 1132, 43-48 (1992).
31. Pommier, Y., Leo, E., Zhang, H. & Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17, 421-433 (2010).
32. Ross, W.E., Glaubiger, D. & Kohn, K.W. Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochim. Biophys. Acta 562, 41-50 (1979).
33. Pommier, Y., Schwartz, R.E., Kohn, K.W. & Zwelling, L.A. Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents. Biochemistry 23, 3194-3201 (1984). (Pubitemid 14056884)
34. Woessner, R.D., Mattern, M.R., Mirabelli, C.K., Johnson, R.K. & Drake, F.H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2, 209-214 (1991).
35. Carpenter, A.J. & Porter, A.C. Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. Mol. Biol. Cell 15, 5700-5711 (2004). (Pubitemid 39564760)
36. Lyu, Y.L. et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 67, 8839-8846 (2007).
37. Zhang, S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639-1642 (2012).
38. Wallace, K.B. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol. Toxicol. 93, 105-115 (2003). (Pubitemid 37108538)
39. Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T. & Schlattner, U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J. Mol. Cell. Cardiol. 41, 389-405 (2006). (Pubitemid 44362995)
40. Sebastiani, M. et al. Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies. J. Am. Coll. Cardiol. 50, 1362-1369 (2007). (Pubitemid 47454690)
41. Sihag, S., Cresci, S., Li, A.Y., Sucharov, C.C. & Lehman, J.J. PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart. J. Mol. Cell. Cardiol. 46, 201-212 (2009).
42. Leone, T.C. & Kelly, D.P. Transcriptional control of cardiac fuel metabolism and mitochondrial function. Cold Spring Harb. Symp. Quant. Biol. 76, 175-182 (2011).
43. Patten, I.S. et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485, 333-338 (2012).
44. Song, W., Song, Y., Kincaid, B., Bossy, B. & Bossy-Wetzel, E. Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1a. Neurobiol. Dis. 51, 72-81 (2013).
45. Sahin, E. et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470, 359-365 (2011).
46. Sardão, V.A., Oliveira, P.J., Holy, J., Oliveira, C.R. & Wallace, K.B. Doxorubicininduced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemother. Pharmacol. 64, 811-827 (2009).
47. Zhu, W. et al. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119, 99-106 (2009).
48. Shizukuda, Y., Matoba, S., Mian, O.Y., Nguyen, T. & Hwang, P.M. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol. Cell. Biochem. 273, 25-32 (2005). (Pubitemid 40774760)
49. Toyoda, E. et al. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J. Biol. Chem. 283, 23711-23720 (2008).
50. Azarova, A.M. et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. U.S.A. 104, 11014-11019 (2007). (Pubitemid 47175218)
51. Kersting, G. et al. Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells. Naunyn Schmiedebergs Arch. Pharmacol. 374, 21-30 (2006).
52. Classen, S., Olland, S. & Berger, J.M. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF- 187. Proc. Natl. Acad. Sci. U.S.A. 100, 10629-10634 (2003). (Pubitemid 37140080)
53. Roca, J., Ishida, R., Berger, J.M., Andoh, T. & Wang, J.C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. U.S.A. 91, 1781-1785 (1994). (Pubitemid 24080289)
54. Pearlman, M., Jendiroba, D., Pagliaro, L., Keyhani, A., Liu, B. & Freireich, E.J. Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. Leuk. Res. 27, 617-626 (2003). (Pubitemid 36398097)
55. Wadler, S., Green, M.D. & Muggia, F.M. Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF 187) against the murine sarcoma S180 cell line. Cancer Res. 46, 1176-1181 (1986). (Pubitemid 16048251)
56. Hasinoff, B.B., Yalowich, J.C., Ling, Y. & Buss, J.L. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer. Drugs 7, 558-567 (1996). (Pubitemid 26276347)
57. Seymour, L., Bramwell, V. & Moran, L.A. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev. Control 3, 145-159 (1999).
58. Swain, S.M. et al. Cardioprotection with dexrazoxane for doxorubicincontaining therapy in advanced breast cancer. J. Clin. Oncol. 15, 1318-1332 (1997). (Pubitemid 27167363)
59. Swain, S.M., Whaley, F.S., Gerber, M.C., Ewer, M.S., Bianchine, J.R. & Gams, R.A. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol. 15, 1333-1340 (1997). (Pubitemid 27167364)
60. Franco, V.I., Henkel, J.M., Miller, T.L. & Lipshultz, S.E. Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol. Res. Pract. 2011, 134679 (2011).
61. Jirkovský, E. et al. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicology 311, 191-204 (2013).
62. Hijiya, N., Ness, K.K., Ribeiro, R.C. & Hudson, M.M. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer 115, 23-35 (2009).
63. Bhatia, S. et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N. Engl. J. Med. 334, 745-751 (1996). (Pubitemid 26089355)
64. Pui, C.H. et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N. Engl. J. Med. 321, 136-142 (1989).
65. Ratain, M.J. et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 70, 1412-1417 (1987). (Pubitemid 18026147)
66. Pui, C.H. et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N. Engl. J. Med. 325, 1682-1687 (1991).
67. Sandoval, C. et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J. Clin. Oncol. 11, 1039-1045 (1993). (Pubitemid 23163342)
68. Le Deley, M.C. et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J. Clin. Oncol. 25, 292-300 (2007).
69. Tebbi, C.K. et al. Dexrazoxane-associated risk for acute myeloid leukemia/ myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J. Clin. Oncol. 25, 493-500 (2007). (Pubitemid 350002954)
70. Vrooman, L.M. et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur. J. Cancer 47, 1373-1379 (2011).
71. Salzer, W.L. et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia 24, 355-370 (2010).
72. US Food and Drug Administration. FDA statement on dexrazoxane. (2011).